Encompass Health Corp. Hits New 52-Week High of $127.99

Encompass Health Corp. has reached a significant milestone by hitting a new 52-week high of USD 127.99 on October 24, 2025. This achievement underscores the company's strong performance in the Pharmaceuticals & Biotechnology sector, where it has demonstrated a remarkable one-year performance of 46.73%, significantly outpacing the S&P 500's 16.9% return.
With a market capitalization of USD 14,505 million, Encompass Health is classified as a small-cap company. The stock's price-to-earnings (P/E) ratio stands at 21.00, reflecting its valuation relative to earnings. Additionally, the company boasts a robust dividend yield of 23.73%, indicating a commitment to returning value to shareholders.

Encompass Health's financial health is further illustrated by a debt-to-equity ratio of 0.89 and a return on equity of 30.38%, showcasing effective management of resources and profitability. The stock's previous 52-week low was recorded at USD 87.85, highlighting the significant upward movement in its price. This new high marks a pivotal moment for Encompass Health Corp. as it continues to navigate the competitive landscape of its industry.